Navigation Links
Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
Date:2/15/2011

NEW YORK, Feb. 15, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

http://www.reportlinker.com/p0386436/Pipeline-Insight-Cancer-Overview--Breast-and-Gynecological-Cancers---Promising-agents-emerge-for-BRCA-positive-patients.html

Introduction

The three tumor types covered in this report are set to account for just over 585,000 new cancer cases in 2010 with forecasts of over 656,000 new cases in 2019. Collectively the drugs profiled in this report for breast and ovarian cancer are forecast to achieve almost $3.0 billion in sales in the seven major pharmaceutical markets in 2019.

Scope of this research

Examination of the breast and ovarian cancer pipelines with in-depth clinical and commercial profiles of Phase III candidates Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions Segmentation and analysis of the current breast and ovarian cancer pipelines by phase of development, drug class and company Insight and analysis of breast, ovarian and cervical cancer markets including commercial opportunity, epidemiology and discussion of unmet needs Research and analysis highlights

There are currently 94 drugs in clinical development for breast cancer, of which 8 are in late phase development (preregistration, Phase III or pivotal Phase II trial). Collectively, the drugs forecast in this report for breast cancer are forecast to achieve $1.1 billion in sales by 2019.

There are currently 41 drugs in the pipeline for ovarian cancer, of which 10 are in late-phase development. Collectively, the drugs in late-phase development for ovarian cancer profiled in this report are forecast to achieve $1.8bn in sales by 2019.

R&D interest in cervical cancer is limited compared with other cancers and as a result there is a lack of novel drug candidates in late-phase development. Despite poor outcomes and prognoses for late-stage patients, recent focus has been directed towards preventative strategies rather than treatment.

Key reasons to purchase this research

Identify key drugs within the breast and ovarian cancer pipelines based on sales forecasts and Datamonitor drug assessment Characterize unmet needs within breast, ovarian and cervical cancers and assess the potential for pipeline products to fulfill them Assess the shifting breast, ovarian and cervical cancer market dynamics and how future treatment will incorporate pipeline products

To order this report:

: Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market
2. Reportlinker Adds Amphotericin B - Comprehensive patent search
3. Reportlinker Adds Therapeutic Proteins to 2014
4. Reportlinker Adds Biochips - Products, Applications, Technologies and End-Use Markets Growth Analysis, 2009-2015
5. Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
6. Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
7. Reportlinker Adds The 2011 Immunoprotein Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country and Market Segment
8. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan Product Development Opportunities and Business Expansion Strategies for Instrumentand Reagent Suppliers
9. Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets
10. Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration
11. Reportlinker Adds Vaccine Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):